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Abstract
The respiratory system is the most common target of COVID-19, however, 
various experimental studies and case reports have shown its affinity for neural 
tissues. In this chapter, we described pathogenesis and propagation of SARS-CoV-2 
virus in the nervous system, potential routes of the SARS-CoV-2 invasion in the 
brain, as well as indirect effects of COVID-19 on multiorgan disorders. We have 
also presented all of the reported neurological manifestations in COVID-19 with an 
explanation of possible underlying pathways. Among patients who tested positive 
on SARS-CoV-2, various neurological irregularities have been described, affecting 
both the central and peripheral nervous systems. In general, neurological complica-
tions in COVID-19 patients occur within 1 and 14 days, in most cases on average 
on the 5th day of the incubation period. We have demonstrated all of the reported 
neurological findings, whereas the most commonly reported were headache, 
dizziness, myalgia, hypogeusia, hyposmia, and impaired consciousness. More 
serious neurological conditions in COVID-19 included meningitis, encephalitis, and 
ischemic or hemorrhagic stroke.
Keywords: SARS-CoV-2, neurologic manifestations, pathogenesis, COVID-19, 
coronavirus
1. Introduction
The infection of coronavirus (SARS-CoV-2) severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) was declared a pandemic by the World Health 
Organization (WHO) on March 11, 2020 [1]. Regarding its structure and infection 
mechanism, SARS-CoV-2 is mostly similar to familiar coronaviruses such as the SARS-
CoV-1 and Middle East respiratory syndrome (MERS) [2, 3]. Identified in Wuhan, 
China, it has abruptly spread all over the world with more than 164.513.450 reported 
cases to date [4]. The respiratory system is the most common target of infection how-
ever, various experimental studies and case reports have shown an affinity for neural 
tissues. Considering observational studies, SARS-CoV-2 patients were registered with 
complaints of headache, nausea, vomiting, dizziness, myalgia, hypogeusia, hyposmia, 
and impaired consciousness, all symptoms that indicate involvement of the nervous 
system [5]. Even though, the exact mechanism which SARS-CoV-2 penetrates the 
central nervous system has not yet been determined, prior experimental models have 
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shown that other coronaviruses can compromise the nervous system and respiratory 
drive by directly targeting neurons located in cardiorespiratory centers [6], due to the 
preliminary observation of cases concerning the COVID-19 pandemic, suggesting a 
higher affinity of SARS-CoV-2 virus for CNS targets.
The aim of this chapter is to present all of the reported neurological manifesta-
tions in COVID-19 with the explanation of possible underlying pathways.
2. COVID-19 and nervous system
In the previous months, reports of meningitis, encephalitis, myelitis, or 
peripheral nerve affection in regard to COVID-19 infection were presented, 
implying that SARS-CoV-2 can directly infect the nervous system.
2.1 Pathogenesis
The SARS-CoV-2 spike protein (S) can bind to the host cellular angiotensin-
converting enzyme 2 (ACE-2) receptor because of its high binding affinity, which is 
of importance to cell tropism [7]. Preparing and processing of the S protein by the 
transmembrane protease serine 2 (TMPRSS2) have been demonstrated to be crucial 
for the synthesis of viral and host cellular membranes, furthermore entrance of 
SARS-CoV-2 [8]. The increased expression of the ACE-2 receptor has been found 
on neurons and glial cells of several brain structures including the cerebral cortex, 
the striatum, the posterior hypothalamic area, the substantia nigra, and brain stem. 
ACE-2 is strongly expressed in the ventrolateral medulla and the nucleus of tractus 
solitarius, both areas involved in the regulation of the respiratory cycle [9].
Arguably, several mechanisms could be taken into account as possible viral 
access routes, such as axonal transport and trans-synaptic transfer, and hematoge-
nous or potentially lymphatic system routes. The infiltration of the CNS through the 
transcribial system describes an infection of the olfactory epithelium continuing 
transmission through the cribriform plate to the subarachnoid space. On the other 
side, the axonal and trans-synaptic transport would combine numerous peripheral 
nerve terminals which leads to contamination by spreading onward neurons (olfac-
tory bulb, the trigeminal nerve, the vagus nerve, etc.) [10].
Another way of CNS infiltration could be through the circulatory system or on 
the other hand, the lymphatic system routes. Transfer over the brain endothelium 
could be accomplished through abluminal virus release into the CNS parenchyma, by 
direct infection of brain microvascular endothelial cells (BMEC), or via endocytosis, 
through virally affected leukocytes or disrupted tight junctions on BMEC-s [11].
However, direct contamination of cells is not the only way of virus transmission. 
Indirect neurotoxicity may be caused by immune system disorders, coagulation 
disorders, cardiovascular comorbidities, disorders of glucose and lipid metabolism, 
hypoxic encephalopathy, and/or gastrointestinal disorders.
Other than ACE-2, SARS-CoV-2 may utilize extracellular matrix metalloprotein-
ase inducer also known as basigin (BSG; CD147) and transmembrane glycoprotein 
neuropilin-1 (NRP1) as receptors. Some enzymes that catalyze proteolysis such 
as TMPRSS11A/B, cathepsin B and L, and furin (FURIN), have been presented to 
promote viral cell entry and replication [12].
2.2 Propagation of SARS-CoV-2 virus in the nervous system
Dissemination of SARS-CoV-2, in which the virus has an effect on peripheral 
neurons via active transport, synaptic terminals, and retrograde transport to the 
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neuronal body of the cell, has been hypothesized [13]. Studies have been conducted, 
explaining the mechanism of trans-synaptic transfer involving the hemagglutinat-
ing encephalomyelitis virus strain 67 N (HEV-67 N), which represents the first 
SARS-CoV-2 strain that was found to infect the porcine cerebrum [14]. Data from 
human single nuclei RNA-seq databases suggest that vascular endothelial cells 
may express ACE-2 in the human cerebrum at low levels, however non-canonical 
SARS-CoV-2 receptors (e.g., BSG/CD147) are displayed in several different brain 
cell types, making them exposed to the virus [15].
2.3 Potential routes of SARS-CoV-2 invasion in brain
Provided by other viruses of the family Coronaviridae, certain possible routes of 
entry for SARS-CoV-2 have been established [16].
2.3.1 Olfactory route
The olfactory nerve (CN I) is the first and shortest cranial nerve. It is a special 
visceral afferent nerve, which transmits information relating to smell. The sense of 
smell is distinguished by olfactory receptors situated within the nasal epithelium. 
Their axons amass into small bundles of olfactory nerves, which infiltrate small 
foramina in the cribriform plate of the ethmoid bone and enter the cranial cavity. 
The absence of the sense of smell is defined as anosmia. A temporary loss of smell 
can be caused by infection or by local disorders, in contrast, a permanent loss of 
smell may be caused by head injury or tumors. Infection of the olfactory system 
is consistent with the observation that loss of smell is a frequent neurological 
manifestation in COVID-19. Some evidence, demonstrate increased MRI signal 
in the olfactory cortex during the acute phase of SARS-CoV-2 infection [17]. As 
represented in the case of other coronaviruses, the virus could be disguised in nerve 
terminals by endocytic mechanisms, transported retrogradely, and spread trans-
synaptically to other regions of the cerebrum [18]. As described before, ACE-2 and 
TMPRSS2 have been identified in the nasal mucosa, epithelial cells (sustentacular 
cells), but not olfactory neurons [19]. However, there are some evidences of neuro-
nal involvement.
2.3.2 Blood: brain route
The blood–brain barrier (BBB) acts as an additional boundary between circulat-
ing blood and the extracellular space of the brain. The barrier is highly selective, 
protecting the brain from toxins, pathogens and even circulating neurotransmitters 
(e.g. glutamate) that can be potentially damaging to neurons. The BBB is a typical 
route of entry of blood-borne viruses into the brain. In SARS-CoV-2 infection, dis-
semination of the virus into the blood has been reported, even though frequencies 
are extensively ranging (1–41%) [16]. Immunoreactivity of ACE-2 was described 
in brain vessels of a patient with multiple ischemic infarcts. However, the cellular 
localization was not resolved. Other receptors, such as NRP1 and BSG, could be 
another possibility of infection due to their more widely expression in the cerebral 
vasculature [20]. Nonetheless, SARS-CoV-2 associated cytokines – interleukins 
(IL-6, IL-1b, IL-17) and tumor necrosis factor (TNF) can potentially damage the 
BBB, which is another way of virus invasion [21]. In several autopsy studies, a lack 
of florid cerebrovascular inflammation has been described [22]. Comorbidities, 
as have oftentimes been seen in COVID-19, such as cardiovascular risk factor or 
pre-existing neurological diseases, in combinations with activation of cytokines, 
increase the permeability of BBB [21].
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2.3.3 Infiltration of infected immune cells
Infected immune cells (monocytes, neutrophils, and T cells) can cause brain 
infestation through the vasculature, the meninges, and choroid plexus [16]. In a 
study conducted by Chen et al., 2020, SARS-CoV-2 nucleocapsid protein (NP) 
immunoreactivity was observed in CD68+ cells in lymphoid organs, while single-
cell RNA seq data showed viral RNA in macrophages of COVID-19 patients [23]. 
However, data about virus proliferation in macrophages are limited due to the 
unknown mechanisms of virus propagation (phagocytic uptake of virus-infected 
cells or extracellular virions) [24].
3. COVID-19 and nervous system: indirect effects of systemic factors
Indirect effects of systemic factors of SARS-CoV-2 can lead to acute and chronic 
consequences, such as respiratory failure, systemic inflammation, hypercoagulable 
state and, lethal systemic organ failure.
3.1 Respiratory failure
SARS-CoV-2 has been predominantly detected in pneumocytes and epithelial 
progenitors, which can lead to potential lung damage, causing massive alveolar 
damage, inflammatory cell infiltration, edema, microvascular thrombosis, and 
hemorrhage resulting in severe hypoxia and acute respiratory distress syndrome 
(ARDS) [25, 26]. The most sensitive brain regions to hypoxia, such as the neocor-
tex, hippocampus, and cerebellum have shown neuronal impairment [27].
3.2 Systemic inflammation
The correlation between immunosuppression and disease severity has been 
established. Most COVID-19 patients have higher circulating levels of IL-6, IL-1b, 
and TNF, but also additionally IL-2, IL-8, IL-17, G-CSF, GM-CSF, IP10, MCP1, and 
MIP1a2, and serum levels of IL-6 and TNF leading to cytokine release syndrome 
[28–30]. After brain entry through the damaged BBB, certain molecules such as 
the nuclear protein high mobility group box 1 (HMGB1), could act as pathogen-
associated molecular patterns (PAMPs) and damage-associated molecular patterns 
(DAMPs) [31]. This process activates an immune response in pericytes, brain 
macrophages, and microglia, which express toll-like receptors (TLR) which act as 
mediators for pro-inflammatory effects of SARS-CoV-2 spike protein on human 
macrophages through nuclear factor-kB (NF-kB) [32]. In this way, immune 
response boosts the level of cytokine production which results in impairment of 
brain function [33].
3.3 Hypercoagulable state
Another vital element of COVID-19 is significant coagulopathy. The multicenter 
study has been conducted, suggesting that 88% of patients displayed evidence of 
a hypercoagulable state. The prothrombin time (PT), activated partial thrombo-
plastin time (aPTT), and complete blood count (CBC) are in the reference range. 
However, fibrinogen level, and fibrin breakdown products indicative of intravascu-
lar thrombosis (D-dimer), are both increased. Coagulopathy may start in the lungs 
causing endothelial damage, complement activation, activation of the procoagulant 
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effect of IL-6, and neutrophil release of extracellular traps (NETs) that leads to the 
formation of a clot, resulting in intravascular thrombosis [34].
3.4 Systemic organ failure
There are many metabolic and pathological evidence of systematic impairment 
in different organs (heart, liver, gastrointestinal tract, and endocrine system) [35]. 
Hypoperfusion of the cerebrum could be impacted by a compromised function of 
the heart [36]. Many neurological symptoms, for instance, headache, confusion, 
agitation, can be correlated to systemic metabolic changes including electrolyte 
disbalance, hormonal dysfunction and accumulation of toxic metabolites [37, 38].
4. COVID-19 and nervous system: neurological manifestations
Although, SARS-CoV-2 is primarily causing the insufficient function of the 
respiratory system, there are overwhelming amounts of evidence implying that 
neurological complications appear as a serious problem in the ongoing COVID-19 
pandemic. In the long-term, COVID-19 could negatively affect the nervous  
system [39].
Among patients who tested positive on SARS-CoV-2, various neurological 
irregularities have been described, affecting both the central and peripheral 
nervous system. Clinical condition and symptoms may vary from mild to severe, 
regardless of patient clinical status (severe form or asymptomatic infection). 
According to Helms et al., neurological abnormalities have been displayed in 30% 
of hospitalized patients, 45% of those with severe respiratory problems, and 85% 
of those who developed ARDS [40]. Patients with mild or asymptomatic infection 
were more likely to develop nonspecific neurological irregularity including head-
ache, dizziness, malaise, and loss of sense of smell and taste.
In the review by Leonardi M, Padovani A, McArthur JC (2020) [41], authors 
have classified the reported neurological findings, into three distinctive categories:
a. Central (headache, dizziness, impaired consciousness, acute cerebrovascular 
disease, seizures, and meningitis/encephalitis)
b. Peripheral (hypogeusia, hyposmia)
c. Musculoskeletal (ischemic or hemorrhagic stroke)
In general, neurological complications in COVID-19 patients occur within 1 and 
14 days, in most cases on average on the 5th day of the incubation period [42].
4.1 Headache and dizziness: central neurological findings
Headache is one of the most commonly reported neurological symptoms of 
a systemic viral infection. Although direct mechanisms of this symptom are yet 
to be discovered, there are some possible causes. High body temperature directly 
causes activation of several immunoinflammatory mediators (cytokines, gluta-
mate,  cyclooxygenase-2/prostaglandin E2 system, and nitric oxide system) and 
activation of substances that are capable of inducing interleukins (exogenous and 
endogenous pyrogens). Some of the indirect causes are dehydration, electrolyte 
disbalance, hypoxia, systemic inflammation, and cytokine release syndrome (CRS). 
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One of the possibilities for developing this symptom could also be direct infection 
of the nervous system via ACE-2 receptors [43].
Vertigo or dizziness has been described as the most common neurological mani-
festation of COVID-19. Neurotropism of SARS-CoV-2 causes the virus to invade 
neural tissue from circulation through capillary endothelium (ACE-2 receptors). 
Aside from this mechanism, direct invasion, hypoxia, and systemic inflammation 
play the part in causing this symptom. Approximately 7.0% (2.5% to 21.4%) of the 
COVID-19 patients were reported to have this symptom.
Combined manifestation of dizziness and headache occurred in 12.1% as has 
been reported in eight studies, with a total of n=654 patients [44].
4.2 Impaired consciousness: central neurological findings
As anticipated, severe or critical patients tend to develop impaired consciousness 
(11.9%) due to hypoxia and cerebrum impairment. In patients with mild or asymp-
tomatic clinical manifestations, the prevalence of this symptom is considerably 
lower (3.2%). The number of studies taken into account was nine, including n=2890 
patients with impaired consciousness [45].
4.3 Acute cerebrovascular complications: central neurological findings
The most common display of cerebrovascular disease is an acute stroke with 
rapidly evolving symptoms which may include weakness of one side of the face 
or body, numbness, motor or sensory aphasia, ataxia, visual impairment. Those 
symptoms could be manifested due to compromised blood supply to the brain and 
which symptom will develop depends on the compromised area of the cerebrum. 
Regarding this clinical problem, two cohort studies were conducted. The first study 
by Mao et al. noted that among 214 hospitalized patients, 6 patients developed acute 
cerebrovascular manifestation (2.8%) [46]. The second study by Li et al. reported 
11 patients with acute ischemic stroke (including a total of 221 COVID-19 patients). 
It has been shown that developing acute cerebrovascular events is highly correlated 
with the age of the patients (71.6 ± 15.7 years/52.1 ± 15.3 years) [47].
4.4 Seizures: central neurological findings
An epileptic seizure is a “transient occurrence of signs and/or symptoms due 
to abnormal excessive or synchronous neuronal activity in the brain” [48]. There 
are few reports of acute seizures in SARS-CoV-2 positive patients. The first study 
regarding this clinical manifestation was noted in a COVID-19 patient, a 24-year-
old male with generalized seizures, from Japan [49]. The second publication 
reported a COVID-19 patient, a 30-year-old female with generalized tonic–clonic 
seizures, from Iran. In both cases, there was no evidence of previous seizures, prior 
to hospitalization [50]. Even though these and similar reports may suggest that cor-
relation between seizures and COVID-19 infection exist, there are a relatively low 
number of reported cases so far, therefore a seizure risk is caused by nonspecific 
mechanisms (hypoxia, cerebrovascular events, cytokine proliferation, etc.).
4.5 Meningitis/encephalitis: central neurological findings
By definition, meningitis is inflammation of the meninges, in almost all cases 
identified by an abnormal number of leukocytes in the cerebrospinal fluid and 
specific symptoms. The etiology may be noninfectious and associated with a 
systemic disease, medication, or other pathologic factors. However, most cases of 
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aseptic meningitis are caused by viruses. There have been interpreted few single-
case reports, regarding meningitis/encephalitis in correlation with COVID-19. 
Anyhow, only a few of reported cases tested positive for SARS-CoV-2. The first 
described case was reported from China, but the amount of clinical evidence was 
underwhelming [51]. Another case was reported in a SARS-CoV-2 positive patient 
from Japan, manifested as generalized seizure and pathological cerebral MRI (right 
lateral ventriculitis and encephalitis mainly on the right mesial temporal lobe and 
hippocampus) [52]. In other reported cases, patients tested negative for SARS-
CoV-2, or even were not tested at all [53].
4.6 Hypogeusia/hyposmia: peripheral neurological findings
The presence of taste and smell alterations seems to be a usual clinical mani-
festation going from 19.4–88% of patients [54]. The specific pathogenesis of 
these issues has not yet been explained. ACE-2 has been distinguished as the cell 
receptor for SARS-CoV-2. These receptors are expressed diffusely on the mucous 
membrane of the entire oral cavity, especially on the tongue and furthermore on 
the nasal mucosa where it takes part in respiratory inflammatory infections by 
regulating the level of inflammatory peptides, for example, bradykinin. There 
have been many reports regarding alteration of the senses of smell and taste. The 
one particular larger study, including a total of 417 patients with mild to moderate 
SARS-CoV-2 infection, described smell impairment in 85.6% and taste impairment 
in 88.8% [55].
4.7 Stroke: musculoskeletal neurological findings
Stroke is commonly defined as sudden neurological deficit as a result of 
infarction or hemorrhage in the central nervous system [56]. This is a traditional 
definition, which has been updated over time with the fact that the neurological 
symptoms need to last more than 24 hours or CT and MRI confirmed focal infarc-
tion or hemorrhage compatible with the symptoms [57]. The typical subdivision 
of stroke includes ischemic stroke (infarction of brain, retina, or spinal infarction) 
and hemorrhagic stroke (intracerebral or subarachnoid hemorrhage) [58]. The 
cause of ischemic stroke is thromboembolism from the small vessel, larger artery, or 
the heart [59]. Classification of the hemorrhagic stroke depends on the anatomical 
location, whereas the most common are supratentorial hemorrhages [60].
There are numerous studies that report acute stroke complicating COVID-19 
[61, 62]. The reported incidence of acute stroke in COVID-19 varies from 0.4% 
to 8.1%, due to the different ethnic and geographical variations: Asia (3.1%), 
Europe (1.2%) and, North America (1.1%) [63]. The reported incidence of stroke 
in COVID-19 patients treated in the intensive care units (ICU) is 1–3% [64–68]. 
Given the extent of the COVID-19 pandemic, this reported incidence is very high. 
Hemorrhagic stroke has been described from 21.7% to 25.7% COVID-19 patients 
with stroke, while the rest were ischemic strokes [69].
It has been stated that male COVID-19 patients, the median age of 63 years, are 
more likely to experience a stroke than women, but it is also known that the major-
ity of ICU COVID-19 patients are older men as well [67]. Other reported risk factors 
include hypertension, diabetes mellitus [66, 70]. Race/ethnicity is also an important 
risk factor and it was observed that the black race had shown the highest prevalence 
(47%) [71]. A severe type of COVID-19 infection was observed as one of the most 
important risk factors for stroke in these patients [72–76]. There is a causal relation-
ship between COVID-19 and stroke since the infection itself is more likely to induce 
thrombotic vascular events [63].
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Described mechanisms of stroke in COVID-19 patients are diverse and multi-
factorial, considering that COVID-19 could be a trigger to typical stroke mecha-
nisms, or alternatively, there are specific pathophysiological mechanisms [63]. The 
mechanisms for ischemic stroke in COVID-19 include sepsis-induced coagulopathy, 
presence of antiphospholipid antibodies, and thromboembolism, which show 
activated coagulation pathway in patients with COVID-19 who ordinarily already 
have elevated D-dimer and fibrinogen [77–81]. It is well known that COVID-19 uses 
the ACE-2 receptor to enter the cells, which leads to increased sympathetic activity, 
loss of blood pressure auto-regulation, and subsequent cerebral hypoperfusion 
[82]. Cytokine storm has also been suggested as one of the mechanisms in stroke 
development in COVID-19, due to its impact on atherosclerosis and thrombosis 
[83]. Finally, hypoxemia in COVID-19 patients may cause cerebral hypoperfusion 
and increase the risk of ischemia, together with previously explained thromboem-
bolic mechanisms [84, 85].
Hemorrhagic strokes are less prevalent than ischemic strokes, but it has been 
implicated that some mechanism which plays a role in ischemic stroke, could lead 
to intracerebral hemorrhage in COVID-19 [86]. The proposed mechanisms include 
viral damage of vessel wall, downregulation of RAS and hypertension, cytokine 
destruction of blood–brain barrier, consumption coagulopathy caused by COVID-19 
and cerebral hypoxia which induces micro-hemorrhages and microbleeds [87, 88]. It 
has been reported that COVID-19 patients who develop stroke are distinctly suscep-
tible to large vessel occlusion, multi-territorial involvement and engagement of else 
ways infrequently affected vessels such as pericallosal artery [66, 68, 89].
Neuroimaging of stroke in COVID-19 patients standardly includes CT, MRI, 
and CT angiography (CTA). Small vessel occlusion in acute ischemic stroke was 
reported in 9% of cases, while large vessel infarctions were seen in almost 65% of 
cases [67, 68, 71, 90]. More frequent were ischemic strokes in posterior circulation 
[91]. It has been demonstrated that CTA verified occlusion in anterior or medial 
cerebral arteries with the co-development of floating thrombi in aorta and carotid 
arteries in patients with high D-dimer values, which confirms the influence of 
hypercoagulable state [71, 92]. Apart from standardly seen ischemic lesions, a small 
number of the patients (two of them were children) with acute stroke had: vascu-
litis or wall enhancement on MRI in the arterial wall [93]. Imaging findings of the 
hemorrhagic stroke include extensive hemispheric hematomas or multiple hema-
tomas [94–97]. Hemorrhages may develop in severely ill patients, especially due to 
the failure of multiple organs or as a transformation of ischemic stroke, aneurysm 
rupture, or thrombosis of central venous sinus [66, 97, 98]. Some authors report a 
possible correlation between COVID-19 and arterial dissection, seen in the carotid 
artery, cervical vertebral artery or in posterior inferior cerebellar artery [99, 100].
A very small samples of patients were presented with acute stroke confirmed on 
neuroimaging and PCR confirmed COVID-19 [101]. Described atypical neuroimaging 
findings are seen in small number of COVID-19 patients with stroke and consist of: 
brain perfusion abnormalities, leptomeningeal enhancement [eight patients], focal 
cortico-pial enhancement in one patient, posterior reversible encephalopathy syn-
drome, microbleeds or leuco-encephalopathy [66, 102, 103]. Atypical findings express 
latent thrombotic angiopathy, vascular disruption and impairment of vascular auto-
regulation of the brain which happens in COVID-19 patients with stroke [103, 104].
5. Conclusions
Even though the COVID-19 virus is primarily a respiratory infection, new 
reported cases of neurological involvement have been presented daily all over the 
9
Neurological Involvement in COVID-19
DOI: http://dx.doi.org/10.5772/intechopen.99309
Author details
Valentina Opancina1*, Kristijan Krstic2, Predrag Sazdanovic3, Nebojsa Zdravkovic4, 
Ruzica Radojevic Marjanovic5 and Radisa Vojinovic1
1 Department of Radiology, Faculty of Medical Sciences, University of Kragujevac, 
Serbia
2 Department of Physical Medicine and Rehabilitation, Faculty of Medical Sciences, 
University of Kragujevac, Serbia
3 Department of Anatomy, Faculty of Medical Sciences, University of Kragujevac, 
Serbia
4 Department of Medical Statistics and Informatics, Faculty of Medical Sciences, 
University of Kragujevac, Serbia
5 Clinic for Infectious Diseases, University Clinical Centre Kragujevac, Serbia
*Address all correspondence to: valentina.opancina@gmail.com
world [105]. In this chapter, we portrayed the neurological manifestations and 
possible pathophysiological mechanisms of SARS-CoV-2 on nervous system [105]. 
Given the extent of the COVID-19 pandemic, it is important to monitor COVID-
19 patients for potential neurological complications to provide them with timely 
diagnostics and treatment.
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